A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

ClinicalTrials.gov ID: NCT01114672

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01114672. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

Study identification

NCT ID: NCT01114672
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Winthrop University Hospital; Other
Enrollment: 50 participants

Conditions and interventions

Conditions

Pruritis

Interventions

50,000 Units Ergocalciferol Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2010 (Type not available)
Primary completion: Nov 2011 (Actual)
Completion: Feb 2012 (Actual)
Last update posted: Feb 21, 2013

2010 – 2012

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 2

Facility	City	State	ZIP	Site status
Winthop Univ Hospital Outpatient Dialysis at Bethpage	Bethpage	New York	11714	—
Winthrop Univ Hospital Outpatient Dialysis	Mineola	New York	11501	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01114672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 21, 2013 · Synced Nov 14, 2026